TransEnterix (TRXDW) Stock Price, News & Analysis

Company Overview

TransEnterix, Inc. was a medical-device company focused on developing and commercializing robotic and digital technologies for minimally invasive surgery. Its primary product was the Senhance Surgical System, a robotic platform designed to support laparoscopic procedures and provide surgeons with features such as ergonomic instrument control, three-dimensional visualization, haptic feedback and digital data capabilities.

The company’s earlier development program included the SurgiBot System, a single-port robotic platform intended for use in minimally invasive procedures. TransEnterix pursued regulatory clearances and commercial opportunities in the United States and international markets, including Europe and Japan, while working with hospitals and surgical teams to expand the use of robotic-assisted surgery.

In 2020, TransEnterix changed its corporate name to Asensus Surgical, reflecting a broader focus on digital surgery and its Senhance platform. The company’s securities have historically traded under different symbols, including warrants associated with its former TransEnterix name. Information about the company should therefore be considered in the context of this corporate rebranding.

Key Stats

• Today's Range: $0.15 to $0.15
• 50-Day Range: $0.15 to $0.15
• 52-Week Range: $0.12 to $0.18
• Volume: N/A
• Average Volume: 8,250 shs
• Market Capitalization: $21.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/05/2020
• Today: 10/16/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: OTCMKTS:TRXDW
• CIK: 876378
• Web: asensus.com
• Phone: +1-919-7658400
• Fax: N/A
• Employees: 170
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): ($4.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$154.20 million
• Net Margins: -2,149.15%
• Pretax Margin: N/A
• Return on Equity: -83.74%
• Return on Assets: -64.94%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 3.24
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $8.53 million
• Price / Sales: 2.51
• Cash Flow: $0.11 per share
• Price / Cash Flow: 1.40
• Book Value: $2.68 per share
• Price / Book: 0.06

Miscellaneous

• Outstanding Shares: 142,777,000
• Free Float: N/A
• Market Cap: $21.42 million
• Optionable: Not Optionable
• Beta: 2.56